메뉴 건너뛰기




Volumn 15, Issue 1, 2013, Pages 15-24

Effects of political conflict-induced treatment interruptions on HIV drug resistance

Author keywords

NNRTI tail; Political crises; Resistance; Treatment interruption; Unplanned

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ASPARAGINE; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LYSINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

EID: 84883059843     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (21)

References (73)
  • 2
    • 44149124010 scopus 로고    scopus 로고
    • Managing antiretroviral therapy: Changing regimens, resistance testing, and the risks from structured treatment interruptions
    • Eron J. Managing antiretroviral therapy: changing regimens, resistance testing, and the risks from structured treatment interruptions. J Infect Dis. 2008;197(Suppl 3):S261-71.
    • (2008) J Infect Dis , vol.197 , Issue.SUPPL. 3
    • Eron, J.1
  • 4
    • 4544267859 scopus 로고    scopus 로고
    • Priority strategies for sustainable fight against HIV/AIDS in low-income countries
    • Dionisio D, Esperti F, Messeri D, Vivarelli A. Priority strategies for sustainable fight against HIV/AIDS in low-income countries. Curr HIV Res. 2004;2:377-93.
    • (2004) Curr HIV Res , vol.2 , pp. 377-393
    • Dionisio, D.1    Esperti, F.2    Messeri, D.3    Vivarelli, A.4
  • 6
    • 0025196791 scopus 로고
    • Health implications of war in Uganda and Sudan
    • Dodge C. Health implications of war in Uganda and Sudan. Soc Sci Med. 1990;31:691-8.
    • (1990) Soc Sci Med , vol.31 , pp. 691-698
    • Dodge, C.1
  • 7
    • 0034660940 scopus 로고    scopus 로고
    • Conflict and health: The health costs of war: Can they be measured? Lessons from El Salvador
    • Ugalde A, Selva-Sutter E, Castillo C, Paz C, Canas S. Conflict and health: The health costs of war: can they be measured? Lessons from El Salvador. BMJ. 2000;321:169-72.
    • (2000) BMJ , vol.321 , pp. 169-172
    • Ugalde, A.1    Selva-Sutter, E.2    Castillo, C.3    Paz, C.4    Canas, S.5
  • 8
    • 0028888527 scopus 로고
    • Public health impact of Rwandan refugee crisis: What happened in Goma, Zaire, in July, 1994
    • Goma Epidemiology Group
    • Goma Epidemiology Group. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994. Lancet. 1995;345: 339-44.
    • (1995) Lancet , vol.345 , pp. 339-344
  • 9
    • 77955999371 scopus 로고    scopus 로고
    • Mortality and health among internally displaced persons in western Kenya following post-election violence, 2008: Novel use of demographic surveillance
    • Feikin D, Adazu K, Obor D, et al. Mortality and health among internally displaced persons in western Kenya following post-election violence, 2008: novel use of demographic surveillance. Bull World Health Organ. 2010;88:601-8.
    • (2010) Bull World Health Organ , vol.88 , pp. 601-608
    • Feikin, D.1    Adazu, K.2    Obor, D.3
  • 11
    • 78049281900 scopus 로고    scopus 로고
    • Treatment interruption in a primary care antiretroviral therapy program in South Africa: Cohort analysis of trends and risk factors
    • Kranzer K, Lewis J, Ford N, et al. Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr. 2010;55:e17-23.
    • (2010) J Acquir Immune Defic Syndr , vol.55
    • Kranzer, K.1    Lewis, J.2    Ford, N.3
  • 12
    • 79956058360 scopus 로고    scopus 로고
    • The consequences of post-election violence on antiretroviral HIV therapy in Kenya
    • Pyne-Mercier L, John-Stewart G, Richardson B, et al. The consequences of post-election violence on antiretroviral HIV therapy in Kenya. AIDS Care. 2011;23:562-8.
    • (2011) AIDS Care , vol.23 , pp. 562-568
    • Pyne-Mercier, L.1    John-Stewart, G.2    Richardson, B.3
  • 13
    • 70350004095 scopus 로고    scopus 로고
    • Impact of the Kenya post-election crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya
    • Vreeman R, Nyandiko W, Sang E, Musick B, Braitstein P, Wiehe S. Impact of the Kenya post-election crisis on clinic attendance and medication adherence for HIV-infected children in western Kenya. Confl Health. 2009;3:5.
    • (2009) Confl Health , vol.3 , pp. 5
    • Vreeman, R.1    Nyandiko, W.2    Sang, E.3    Musick, B.4    Braitstein, P.5    Wiehe, S.6
  • 14
    • 33846024773 scopus 로고    scopus 로고
    • Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults
    • Pai N, Lawrence J, Reingold A, Tulsky J. Structured treatment interruptions (STI) in chronic unsuppressed HIV infection in adults. Cochrane Database Syst Rev. 2006;3:CD006148.
    • (2006) Cochrane Database Syst Rev , vol.3
    • Pai, N.1    Lawrence, J.2    Reingold, A.3    Tulsky, J.4
  • 16
    • 80052873078 scopus 로고    scopus 로고
    • Unstructured treatment interruption of antiretroviral therapy in clinical practice: A systematic review
    • Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011;16:1297-313.
    • (2011) Trop Med Int Health , vol.16 , pp. 1297-1313
    • Kranzer, K.1    Ford, N.2
  • 17
    • 0036283755 scopus 로고    scopus 로고
    • Political violence, ethnic conflict, and contemporary wars: Broad implications for health and social well-being
    • Pedersen D. Political violence, ethnic conflict, and contemporary wars: broad implications for health and social well-being. Soc Sci Med. 2002;55:175-90.
    • (2002) Soc Sci Med , vol.55 , pp. 175-190
    • Pedersen, D.1
  • 19
    • 84883114240 scopus 로고    scopus 로고
    • (Accessed July 07,)
    • A Country Study: El Salvador. (Available at: at http://lcweb2.loc.gov/ frd/cs/svtoc.html. Accessed July 07, 2011).
    • (2011) A Country Study: El Salvador
  • 20
    • 77950386666 scopus 로고    scopus 로고
    • Unplanned antiretroviral treatment interruptions in southern Africa: How should we be managing these?
    • Veenstra N, Whiteside A, Lalloo D, Gibbs A. Unplanned antiretroviral treatment interruptions in southern Africa: how should we be managing these? Global Health. 2010;6:4.
    • (2010) Global Health , vol.6 , pp. 4
    • Veenstra, N.1    Whiteside, A.2    Lalloo, D.3    Gibbs, A.4
  • 21
    • 70349984153 scopus 로고    scopus 로고
    • Providing HIV care in the aftermath of Kenya's post-election violence Medecins Sans Frontieres' lessons learned January - March 2008
    • Reid T, van Engelgem I, Telfer B, Manzi M. Providing HIV care in the aftermath of Kenya's post-election violence Medecins Sans Frontieres' lessons learned January - March 2008. Confl Health. 2008;2:15.
    • (2008) Confl Health , vol.2 , pp. 15
    • Reid, T.1    Van Engelgem, I.2    Telfer, B.3    Manzi, M.4
  • 22
    • 77649224899 scopus 로고    scopus 로고
    • Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach
    • Geng E, Bangsberg D, Musinguzi N, et al. Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. J Acquir Immune Defic Syndr. 2010;53:405-11.
    • (2010) J Acquir Immune Defic Syndr , vol.53 , pp. 405-411
    • Geng, E.1    Bangsberg, D.2    Musinguzi, N.3
  • 23
    • 13944262121 scopus 로고    scopus 로고
    • A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection
    • Cardiello P, Hassink E, Ananworanich J, et al. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Clin Infect Dis. 2005;40:594-600.
    • (2005) Clin Infect Dis , vol.40 , pp. 594-600
    • Cardiello, P.1    Hassink, E.2    Ananworanich, J.3
  • 24
    • 23244437092 scopus 로고    scopus 로고
    • Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 study
    • Ananworanich J, Siangphoe U, Hill A, et al. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study. J Acquir Immune Defic Syndr. 2005; 39:523-9.
    • (2005) J Acquir Immune Defic Syndr , vol.39 , pp. 523-529
    • Ananworanich, J.1    Siangphoe, U.2    Hill, A.3
  • 25
    • 33746479812 scopus 로고    scopus 로고
    • CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: Results of the Staccato randomised trial
    • Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006;368:459-65.
    • (2006) Lancet , vol.368 , pp. 459-465
    • Ananworanich, J.1    Gayet-Ageron, A.2    Le Braz, M.3
  • 26
    • 77956405792 scopus 로고    scopus 로고
    • A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda
    • Reynolds S, Kityo C, Hallahan C, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One. 2010;5:e10307.
    • (2010) PLoS One , vol.5
    • Reynolds, S.1    Kityo, C.2    Hallahan, C.3
  • 27
    • 34447304106 scopus 로고    scopus 로고
    • A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164)
    • Walmsley S, Thorne A, Loutfy M, et al. A prospective randomized controlled trial of structured treatment interruption in HIV-infected patients failing highly active antiretroviral therapy (Canadian HIV Trials Network Study 164). J Acquir Immune Defic Syndr. 2007;45:418-25.
    • (2007) J Acquir Immune Defic Syndr , vol.45 , pp. 418-425
    • Walmsley, S.1    Thorne, A.2    Loutfy, M.3
  • 28
    • 77952822874 scopus 로고    scopus 로고
    • Guidelines for the use of antiretroviral agents in Hiv-1-infected adults and adolescents
    • DHHS. Department of Health and Human Services
    • DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents 2011.
    • (2011) Panel on Antiretroviral Guidelines for Adults and Adolescents
  • 29
    • 77954692660 scopus 로고    scopus 로고
    • Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel
    • Thompson M, Aberg J, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304:321-33.
    • (2010) JAMA , vol.304 , pp. 321-333
    • Thompson, M.1    Aberg, J.2    Cahn, P.3
  • 30
    • 60549096626 scopus 로고    scopus 로고
    • Dynamics of NRTI resistance mutations during therapy interruption
    • Trignetti M, Sing T, Svicher V, et al. Dynamics of NRTI resistance mutations during therapy interruption. AIDS Res Hum Retroviruses. 2009;25:57-64.
    • (2009) AIDS Res Hum Retroviruses , vol.25 , pp. 57-64
    • Trignetti, M.1    Sing, T.2    Svicher, V.3
  • 31
    • 58749091289 scopus 로고    scopus 로고
    • Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: A randomized trial involving West African adults
    • Danel C, Moh R, Chaix M, et al. Two-months-off, four-months-on antiretroviral regimen increases the risk of resistance, compared with continuous therapy: a randomized trial involving West African adults. J Infect Dis. 2009;199:66-76.
    • (2009) J Infect Dis , vol.199 , pp. 66-76
    • Danel, C.1    Moh, R.2    Chaix, M.3
  • 32
    • 0024273119 scopus 로고
    • The accuracy of reverse transcriptase from HIV-1
    • Roberts J, Bebenek K, Kunkel T. The accuracy of reverse transcriptase from HIV-1. Science. 1988;242:1171-3.
    • (1988) Science , vol.242 , pp. 1171-1173
    • Roberts, J.1    Bebenek, K.2    Kunkel, T.3
  • 33
    • 77957658175 scopus 로고    scopus 로고
    • Quasispecies theory and the behavior of RNA viruses
    • Lauring A, Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010;6:e1001005.
    • (2010) PLoS Pathog , vol.6
    • Lauring, A.1    Andino, R.2
  • 34
    • 79952836893 scopus 로고    scopus 로고
    • Singlenucleotide changes in the HIV Rev-response element mediate resistance to compounds that inhibit Rev function
    • Shuck-Lee D, Chang H, Sloan E, Hammarskjold M, Rekosh D. Singlenucleotide changes in the HIV Rev-response element mediate resistance to compounds that inhibit Rev function. J Virol. 2011;85:3940-9.
    • (2011) J Virol , vol.85 , pp. 3940-3949
    • Shuck-Lee, D.1    Chang, H.2    Sloan, E.3    Hammarskjold, M.4    Rekosh, D.5
  • 35
    • 34249341728 scopus 로고    scopus 로고
    • Adherence-resistance relationships to combination HIV antiretroviral therapy
    • Bangsberg D, Kroetz D, Deeks S. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep. 2007; 4:65-72.
    • (2007) Curr HIV/AIDS Rep , vol.4 , pp. 65-72
    • Bangsberg, D.1    Kroetz, D.2    Deeks, S.3
  • 36
    • 34250733532 scopus 로고    scopus 로고
    • Risk of selecting resistance mutations during treatment interruption
    • Martinez-Picado J, Wai Yan Tam L. Risk of selecting resistance mutations during treatment interruption. Curr Opin HIV AIDS. 2007;2:6-13.
    • (2007) Curr Opin HIV AIDS , vol.2 , pp. 6-13
    • Martinez-Picado, J.1    Wai Yan Tam, L.2
  • 37
    • 67651085608 scopus 로고    scopus 로고
    • Antiretroviral medication adherence and the development of class-specific antiretroviral resistance
    • Gardner E, Burman W, Steiner J, Anderson P, Bangsberg D. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23:1035-46.
    • (2009) AIDS , vol.23 , pp. 1035-1046
    • Gardner, E.1    Burman, W.2    Steiner, J.3    Anderson, P.4    Bangsberg, D.5
  • 38
    • 0141518673 scopus 로고    scopus 로고
    • Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-tochild transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
    • Jackson J, Musoke P, Fleming T, et al. Intrapartum and neonatal singledose nevirapine compared with zidovudine for prevention of mother-tochild transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859-68.
    • (2003) Lancet , vol.362 , pp. 859-868
    • Jackson, J.1    Musoke, P.2    Fleming, T.3
  • 39
    • 40049106667 scopus 로고    scopus 로고
    • Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy
    • Lockman S. Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy. Curr Opin HIV AIDS. 2008;3:166-72.
    • (2008) Curr Opin HIV AIDS , vol.3 , pp. 166-172
    • Lockman, S.1
  • 40
    • 77957945728 scopus 로고    scopus 로고
    • Antiretroviral therapies in women after single-dose nevirapine exposure
    • Lockman S, Hughes M, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med. 2010;363:1499-509.
    • (2010) N Engl J Med , vol.363 , pp. 1499-1509
    • Lockman, S.1    Hughes, M.2    McIntyre, J.3
  • 42
    • 72249123176 scopus 로고    scopus 로고
    • Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action
    • Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentre F, Taburet A. Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action. Clin Pharmacokinet. 2010;49:17-45.
    • (2010) Clin Pharmacokinet , vol.49 , pp. 17-45
    • Bazzoli, C.1    Jullien, V.2    Le Tiec, C.3    Rey, E.4    Mentre, F.5    Taburet, A.6
  • 44
    • 84883098104 scopus 로고    scopus 로고
    • Hansen K, Parthasarathi G, ed.: Orient Blackswan
    • Text Book Of Clinical Pharmacy. Hansen K, Parthasarathi G, ed.: Orient Blackswan; 2004.
    • (2004) Text Book of Clinical Pharmacy
  • 46
    • 70049100021 scopus 로고    scopus 로고
    • HIV-1 resistance to first- and secondgeneration non-nucleoside reverse transcriptase inhibitors
    • Ghosn J, Chaix M, Delaugerre C. HIV-1 resistance to first- and secondgeneration non-nucleoside reverse transcriptase inhibitors. AIDS Rev. 2009;11:165-73.
    • (2009) AIDS Rev , vol.11 , pp. 165-173
    • Ghosn, J.1    Chaix, M.2    Delaugerre, C.3
  • 47
    • 67449097569 scopus 로고    scopus 로고
    • Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: A systematic review and metaanalysis
    • Gupta R, Hill A, Sawyer A, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and metaanalysis. Lancet Infect Dis. 2009;9:409-17.
    • (2009) Lancet Infect Dis , vol.9 , pp. 409-417
    • Gupta, R.1    Hill, A.2    Sawyer, A.3
  • 48
    • 79952414942 scopus 로고    scopus 로고
    • Global trends in molecular epidemiology of HIV-1 during 2000-2007
    • Hemelaar J, Gouws E, Ghys P, Osmanov S. Global trends in molecular epidemiology of HIV-1 during 2000-2007. AIDS. 2011;25:679-89.
    • (2011) AIDS , vol.25 , pp. 679-689
    • Hemelaar, J.1    Gouws, E.2    Ghys, P.3    Osmanov, S.4
  • 49
    • 1042287077 scopus 로고    scopus 로고
    • Drug resistance in non-subtype B HIV-1
    • Kantor R, Katzenstein D. Drug resistance in non-subtype B HIV-1. J Clin Virol. 2004;29:152-9.
    • (2004) J Clin Virol , vol.29 , pp. 152-159
    • Kantor, R.1    Katzenstein, D.2
  • 50
    • 19344373478 scopus 로고    scopus 로고
    • Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration
    • Kantor R, Katzenstein D, Efron B, et al. Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med. 2005;2:e112.
    • (2005) PLoS Med , vol.2
    • Kantor, R.1    Katzenstein, D.2    Efron, B.3
  • 51
    • 33750519867 scopus 로고    scopus 로고
    • Impact of HIV-1 pol diversity on drug resistance and its clinical implications
    • Kantor R. Impact of HIV-1 pol diversity on drug resistance and its clinical implications. Curr Opin Infect Dis. 2006;19:594-606.
    • (2006) Curr Opin Infect Dis , vol.19 , pp. 594-606
    • Kantor, R.1
  • 52
    • 0038298453 scopus 로고    scopus 로고
    • Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution
    • Kantor R, Katzenstein D. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev. 2003;5:25-35.
    • (2003) AIDS Rev , vol.5 , pp. 25-35
    • Kantor, R.1    Katzenstein, D.2
  • 53
    • 24144438597 scopus 로고    scopus 로고
    • Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after singledose nevirapine: HIVNET 012
    • Eshleman S, Guay L, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after singledose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr. 2005;40:24-9.
    • (2005) J Acquir Immune Defic Syndr , vol.40 , pp. 24-29
    • Eshleman, S.1    Guay, L.2    Wang, J.3
  • 54
    • 80053062468 scopus 로고    scopus 로고
    • The search for a cure for persistent HIV reservoirs
    • Lafeuillade A, Stevenson M. The search for a cure for persistent HIV reservoirs. AIDS Rev. 2011;13:63-6.
    • (2011) AIDS Rev , vol.13 , pp. 63-66
    • Lafeuillade, A.1    Stevenson, M.2
  • 55
    • 77957063611 scopus 로고    scopus 로고
    • Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection
    • Turriziani O, Andreoni M, Antonelli G. Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clin Microbiol Infect. 2010;16:1518-24.
    • (2010) Clin Microbiol Infect , vol.16 , pp. 1518-1524
    • Turriziani, O.1    Andreoni, M.2    Antonelli, G.3
  • 56
    • 17444367748 scopus 로고    scopus 로고
    • The latent HIV-1 reservoir in patients undergoing HAART: An archive of pre-HAART drug resistance
    • Noe A, Plum J, Verhofstede C. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance. J Antimicrob Chemother. 2005;55:410-2.
    • (2005) J Antimicrob Chemother , vol.55 , pp. 410-412
    • Noe, A.1    Plum, J.2    Verhofstede, C.3
  • 58
    • 52749083531 scopus 로고    scopus 로고
    • British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008
    • Gazzard B, Anderson J, Babiker A, et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9:563-608.
    • (2008) HIV Med , vol.9 , pp. 563-608
    • Gazzard, B.1    Anderson, J.2    Babiker, A.3
  • 60
    • 0032562117 scopus 로고    scopus 로고
    • Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group
    • Rachlis A, Zarowny D. Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group. CMAJ. 1998;158:496-505.
    • (1998) CMAJ , vol.158 , pp. 496-505
    • Rachlis, A.1    Zarowny, D.2
  • 61
    • 33751515147 scopus 로고    scopus 로고
    • CD4+ count-guided interruption of antiretroviral treatment
    • El-Sadr W, Lundgren J, Neaton J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-96.
    • (2006) N Engl J Med , vol.355 , pp. 2283-2296
    • El-Sadr, W.1    Lundgren, J.2    Neaton, J.3
  • 62
    • 67649666969 scopus 로고    scopus 로고
    • CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART
    • Maggiolo F, Airoldi M, Callegaro A, et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS. 2009;23:799-807.
    • (2009) AIDS , vol.23 , pp. 799-807
    • Maggiolo, F.1    Airoldi, M.2    Callegaro, A.3
  • 63
    • 33745003258 scopus 로고    scopus 로고
    • CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): A randomised trial
    • Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet. 2006;367:1981-9.
    • (2006) Lancet , vol.367 , pp. 1981-1989
    • Danel, C.1    Moh, R.2    Minga, A.3
  • 64
    • 34147185711 scopus 로고    scopus 로고
    • Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN)
    • Pogany K, van Valkengoed I, Prins J, et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week Treatment Interruption in Early Starters Netherlands Study (TRIESTAN). J Acquir Immune Defic Syndr. 2007;44:395-400.
    • (2007) J Acquir Immune Defic Syndr , vol.44 , pp. 395-400
    • Pogany, K.1    Van Valkengoed, I.2    Prins, J.3
  • 65
    • 33845921356 scopus 로고    scopus 로고
    • Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients
    • Ruiz L, Paredes R, Gomez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS. 2007;21:169-78.
    • (2007) AIDS , vol.21 , pp. 169-178
    • Ruiz, L.1    Paredes, R.2    Gomez, G.3
  • 66
    • 57649228971 scopus 로고    scopus 로고
    • Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption
    • Leon A, Martinez E, Milinkovic A, et al. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption. J Antimicrob Chemother. 2009;63:184-8.
    • (2009) J Antimicrob Chemother , vol.63 , pp. 184-188
    • Leon, A.1    Martinez, E.2    Milinkovic, A.3
  • 67
    • 37549062973 scopus 로고    scopus 로고
    • Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl
    • DART Trial Team
    • DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS. 2008;22:237-47.
    • (2008) AIDS , vol.22 , pp. 237-247
  • 68
    • 1642339461 scopus 로고    scopus 로고
    • Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial
    • Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS. 2004;18:439-46.
    • (2004) AIDS , vol.18 , pp. 439-446
    • Maggiolo, F.1    Ripamonti, D.2    Gregis, G.3    Quinzan, G.4    Callegaro, A.5    Suter, F.6
  • 69
    • 33847794452 scopus 로고    scopus 로고
    • Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death
    • Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med. 2007;8:96-104.
    • (2007) HIV Med , vol.8 , pp. 96-104
    • Holkmann Olsen, C.1    Mocroft, A.2    Kirk, O.3
  • 70
    • 20144370827 scopus 로고    scopus 로고
    • Interruption of highly active antiretroviral therapy in HIV clinical practice: Results from the Italian Cohort of Antiretroviral-Naive Patients
    • d'arminio Monforte A, Cozzi-Lepri A, Phillips A, et al. Interruption of highly active antiretroviral therapy in HIV clinical practice: results from the Italian Cohort of Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr. 2005;38:407-16.
    • (2005) J Acquir Immune Defic Syndr , vol.38 , pp. 407-416
    • D'Arminio Monforte, A.1    Cozzi-Lepri, A.2    Phillips, A.3
  • 71
    • 79951517916 scopus 로고    scopus 로고
    • Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death
    • Kaufmann G, Elzi L, Weber R, et al. Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. AIDS. 2011;25:441-51.
    • (2011) AIDS , vol.25 , pp. 441-451
    • Kaufmann, G.1    Elzi, L.2    Weber, R.3
  • 72
    • 67449146275 scopus 로고    scopus 로고
    • Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up
    • Knobel H, Urbina O, Gonzalez A, et al. Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up. HIV Med. 2009;10:364-9.
    • (2009) HIV Med , vol.10 , pp. 364-369
    • Knobel, H.1    Urbina, O.2    Gonzalez, A.3
  • 73
    • 20044394359 scopus 로고    scopus 로고
    • Long-term consequences of treatment interruptions in chronically HIV-1-infected patients
    • Wolf E, Hoffmann C, Procaccianti M, et al. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients. Eur J Med Res. 2005;10:56-62.
    • (2005) Eur J Med Res , vol.10 , pp. 56-62
    • Wolf, E.1    Hoffmann, C.2    Procaccianti, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.